Monitoring of Metabolic Adverse Events of Second-generation Antipsychotics in a Naive Paediatric Population Followed in Mental Health Outpatient and Inpatient Clinical Settings: MEMAS Prospective Study Protocol

Overview

Journal BMJ Open

Specialty General Medicine

Date 2021 Jan 18

PMID 33455928

Authors

Marie-Line Menard

Drigissa Ilies

Pascale Abadie

Thaina Jean-Baptiste

Rachel Choquette

Anne-Sophie Huet

Leila Ben Amor

Affiliations

Soon will be listed here.

Abstract

Introduction: Second-generation antipsychotics (SGAs) are widely used in the paediatric population. It is currently established that SGAs may induce metabolic adverse events (AEs) such as weight gain, perturbation of blood lipids or glucose with risk of potential cardiovascular morbidity and mortality. The Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in children (CAMESA) has published recommendations for monitoring the metabolic AEs of SGAs. Factors that may be associated with the onset of SGA's metabolic AEs and long-term consequences are less studied in the literature. The objectives of our research are to evaluate some factors that can influence the development of the SGA's metabolic AEs and to study clinical adherence to CAMESA guidelines.

Methods And Analysis: The Monitoring des Effets Métaboliques des Antipsychotiques de Seconde Génération study is a multicenter, prospective, longitudinal observational study with repeated measures of metabolic monitoring over 24 months. Two recruiting centres have been selected for patients under 18 years of age, previously naive of antipsychotics, starting an SGA or who have started an SGA for less than 4 weeks regardless of the diagnosis that motivated the prescription. Assessments are performed for anthropometric measures, blood pressure, blood tests at baseline and 1, 2, 3, 6, 9, 12 and 24 months of follow-up.

Ethics And Dissemination: The study protocol was approved by the CHU Sainte-Justine's Research Ethics Board (MP-21-2016-1201) in 2016 and obtained institutional suitability for the 'Centre Intégré Universitaire de Santé et de Services Sociaux du Nord-de-l'Île-de-Montréal' Research Center in May 2018. For all participants, written consent will be obtained from parents/caregivers as well as the participant's assent in order to enable their participation in this research project. The results of this research will be published.

Trial Registration Number: ClinicalTrials.gov (number NCT04395326).

References

Motl R, Dishman R, Trost S, Saunders R, Dowda M, Felton G . Factorial validity and invariance of questionnaires measuring social-cognitive determinants of physical activity among adolescent girls. Prev Med. 2000; 31(5):584-94. DOI: 10.1006/pmed.2000.0735. View

. National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics. 1992; 89(3):495-501. View

Hardie Murphy M, Rowe D, Belton S, B Woods C . Validity of a two-item physical activity questionnaire for assessing attainment of physical activity guidelines in youth. BMC Public Health. 2015; 15:1080. PMC: 4619274. DOI: 10.1186/s12889-015-2418-6. View

Correll C, Manu P, Olshanskiy V, Napolitano B, Kane J, Malhotra A . Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009; 302(16):1765-73. PMC: 3055794. DOI: 10.1001/jama.2009.1549. View

Chen X, Beydoun M, Wang Y . Is sleep duration associated with childhood obesity? A systematic review and meta-analysis. Obesity (Silver Spring). 2008; 16(2):265-74. DOI: 10.1038/oby.2007.63. View

McClellan J, Stock S . Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 2013; 52(9):976-90. DOI: 10.1016/j.jaac.2013.02.008. View

Arango C, Giraldez M, Merchan-Naranjo J, Baeza I, Castro-Fornieles J, Alda J . Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients. J Am Acad Child Adolesc Psychiatry. 2014; 53(11):1179-90,1190.e1-4. DOI: 10.1016/j.jaac.2014.08.009. View

Katzmarzyk P . Waist circumference percentiles for Canadian youth 11-18y of age. Eur J Clin Nutr. 2004; 58(7):1011-5. DOI: 10.1038/sj.ejcn.1601924. View

LeBlanc A, Broyles S, Chaput J, Leduc G, Boyer C, Borghese M . Correlates of objectively measured sedentary time and self-reported screen time in Canadian children. Int J Behav Nutr Phys Act. 2015; 12:38. PMC: 4381481. DOI: 10.1186/s12966-015-0197-1. View

10.

McClellan J, Kowatch R, Findling R . Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2007; 46(1):107-125. DOI: 10.1097/01.chi.0000242240.69678.c4. View

11.

Ho J, Panagiotopoulos C, McCrindle B, Grisaru S, Pringsheim T . Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth. Paediatr Child Health. 2012; 16(9):575-80. PMC: 3223901. View

12.

Correll C, Sheridan E, DelBello M . Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord. 2010; 12(2):116-41. DOI: 10.1111/j.1399-5618.2010.00798.x. View

13.

Marcus R, Owen R, Manos G, Mankoski R, Kamen L, McQuade R . Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. J Clin Psychiatry. 2011; 72(9):1270-6. DOI: 10.4088/JCP.09m05933. View

14.

Schmitz K, Harnack L, Fulton J, Jacobs Jr D, Gao S, Lytle L . Reliability and validity of a brief questionnaire to assess television viewing and computer use by middle school children. J Sch Health. 2005; 74(9):370-7. DOI: 10.1111/j.1746-1561.2004.tb06632.x. View

15.

Martinez-Ortega J, Funes-Godoy S, Diaz-Atienza F, Gutierrez-Rojas L, Perez-Costillas L, Gurpegui M . Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review. Eur Child Adolesc Psychiatry. 2013; 22(8):457-79. DOI: 10.1007/s00787-013-0399-5. View

16.

Rubin D, Kreider A, Matone M, Huang Y, Feudtner C, Ross M . Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths. JAMA Pediatr. 2015; 169(4):e150285. DOI: 10.1001/jamapediatrics.2015.0285. View

17.

Rodday A, Parsons S, Mankiw C, Correll C, Robb A, Zima B . Child and adolescent psychiatrists' reported monitoring behaviors for second-generation antipsychotics. J Child Adolesc Psychopharmacol. 2015; 25(4):351-61. PMC: 4442598. DOI: 10.1089/cap.2014.0156. View

18.

Vereecken C, Maes L . A Belgian study on the reliability and relative validity of the Health Behaviour in School-Aged Children food-frequency questionnaire. Public Health Nutr. 2003; 6(6):581-8. DOI: 10.1079/phn2003466. View

19.

Ronsley R, Nguyen D, Davidson J, Panagiotopoulos C . Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study. Can J Psychiatry. 2016; 60(10):441-50. PMC: 4679120. DOI: 10.1177/070674371506001005. View

20.

Nielsen R, Frahm Laursen M, Vernal D, Bisgaard C, Jakobsen H, Steinhausen H . Risk of diabetes in children and adolescents exposed to antipsychotics: a nationwide 12-year case-control study. J Am Acad Child Adolesc Psychiatry. 2014; 53(9):971-979.e6. DOI: 10.1016/j.jaac.2014.04.023. View